Loading...
Market
Number of Humira biosimilars in CVS formulary by end of 2024
5
Resolution / Starting Odds
Remains 9 • 25%
10 to 12 • 25%
13 to 15 • 25%
More than 15 • 25%
Official announcements from CVS Health
Story
CVS Health Switch to Hyrimoz Biosimilar Captures 36% Market Share
Apr 16, 2024, 02:25 PM
Following a strategic shift by CVS Health, the prescription of biosimilar versions of Humira, notably Hyrimoz, has seen a significant surge. CVS Health, through its PBM Caremark which covers approximately 30 million US patients, removed Humira from its formulary on April 1st and replaced it with Hyrimoz, marketed by CVS's subsidiary Cordavis. This change led to an increase in Hyrimoz prescriptions from 640 to 8300 in just one week, capturing a market share of 36% from just 5%. The market share for Hyrimoz notably increased, while other Humira biosimilars did not experience similar growth. Approximately half of the new prescriptions for Humira biosimilars were for Hyrimoz, despite there being nine different biosimilars available in the U.S. market.
View original story
Similar markets
Less than 30% • 25%
30% to 50% • 25%
51% to 70% • 25%
More than 70% • 25%
No change • 25%
Increase by up to 20% • 25%
Increase by 21% to 40% • 25%
Increase more than 40% • 25%
0-2 competitors • 25%
3-5 competitors • 25%
6-8 competitors • 25%
More than 8 competitors • 25%
No new approvals • 25%
1 new approval • 25%
2 new approvals • 25%
3 or more new approvals • 25%
Less than 5 • 25%
5 to 9 • 25%
10 to 14 • 25%
15 or more • 25%
0-5 • 20%
6-10 • 20%
11-15 • 20%
16-20 • 20%
More than 20 • 20%
Less than 10 • 33%
10-20 • 34%
More than 20 • 33%
Zero • 25%
One • 25%
Two • 25%
Three or more • 25%
Biosimilars launched • 50%
Biosimilars not launched • 50%
0-5 contracts • 25%
6-10 contracts • 25%
11-15 contracts • 25%
More than 15 contracts • 25%
0-5 cases • 25%
6-10 cases • 25%
11-20 cases • 25%
More than 20 cases • 25%